ArticleNature communications2020
Mode of action of teixobactins in cellular membranes.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 96 citations in OpenAlex.
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues.Biomolecules · 2026Article
- Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by LipidBiochemistry · 2026Article
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- Exploring the Phytochemical Profile and Biological Activities, Supported by Molecular Docking and Dynamics Simulation Studies of Lysimachia tyrrhenia U.Manns & Anderb.Chemistry & biodiversity · 2026Article
- Heteroaryl Bishydrazono Nitroimidazoles: A Unique Structural Skeleton with Potent Multitargeting Antibacterial Activity.International journal of molecular sciences · 2025Article
- Mining Microbial Dark Matter: Advanced Cultivation Techniques for Bioactive Compound Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Mechanism, Efficacy, and Safety of Natural Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Novltex: A New Class of Antibiotics with Potent Activity against Multidrug-Resistant Bacterial Pathogens─Design, Synthesis, and Biological Evaluation.Journal of medicinal chemistry · 2025Article
- Hijacking the Electron Train: Menaquinone-Binding Antimicrobial Peptides.Chembiochem : a European journal of chemical biology · 2025Review
- Systematic Determination of the Impact of Structural Edits on Peptide Accumulation into Mycobacteria.ACS chemical biology · 2025Article
- The combined effects of tick defensin persulcatusin with conventional antibiotics and antimicrobial proteins/peptides againstMicrobiology (Reading, England) · 2025Article
- A Comprehensive Review of Molecular Mechanisms Leading to the Emergence of Multidrug Resistance in Bacteria.Indian journal of microbiology · 2025Review
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Vancomycin-Teixobactin Conjugates.Journal of the American Chemical Society · 2025Article
- Drug repurposing of natural depsipeptide fromFrontiers in pharmacology · 2025Article
- Structure-Activity Relationship Studies of the Peptide Antibiotic Clovibactin.The Journal of organic chemistry · 2024Article
- Investigation of Isobactin Analogues of Teixobactin.ACS medicinal chemistry letters · 2024Article
- Host defence peptide plectasin targets bacterial cell wall precursor lipid II by a calcium-sensitive supramolecular mechanism.Nature microbiology · 2024Article
- Supramolecular Interactions of Teixobactin Analogues in the Crystal State.The Journal of organic chemistry · 2024Article
- New Teixobactin Analogues with a Total Lactam Ring.ACS medicinal chemistry letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural antibiotic teixobactin kills pathogenic bacteria without detectable resistance. The difficult synthesis and unfavourable solubility of teixobactin require modifications, yet insufficient knowledge on its binding mode impedes the hunt for superior analogues. Thus far, teixobactins are assumed to kill bacteria by binding to cognate cell wall precursors (Lipid II and III). Here we present the binding mode of teixobactins in cellular membranes using solid-state NMR, microscopy, and affinity assays. We solve the structure of the complex formed by an improved teixobactin-analogue and Lipid II and reveal how teixobactins recognize a broad spectrum of targets. Unexpectedly, we find that teixobactins only weakly bind to Lipid II in cellular membranes, implying the direct interaction with cell wall precursors is not the sole killing mechanism. Our data suggest an additional mechanism affords the excellent activity of teixobactins, which can block the cell wall biosynthesis by capturing precursors in massive clusters on membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.